Kiniksa Pharmaceuticals International, Plc - 10-Q Summary (Q1 2026)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Kiniksa Pharmaceuticals International, Plc is a biopharmaceutical company focused on cardiovascular indications. Its primary commercial product is ARCALYST (anakinra), used for recurrent pericarditis and other rare diseases. The company is advancing a pipeline including KPL-387 (recurrent pericarditis) and KPL-1161 (pre-clinical), while discontinuing development of abiprubart.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $214.3 million | $137.8 million |
| Net Income | $22.6 million | $8.5 million |
| Diluted EPS | $0.27 | $0.11 |
| Operating Cash Flow | $50.2 million | $22.3 million |
| Cash & Short-Term Investments | $468.1 million | $414.1 million |
| Debt | None reported | None reported |
Margins: Gross margin (Revenue minus Cost of Goods Sold) was approximately 90.3% in Q1 2026. Operating margin was approximately 13.7%.
Material Changes vs. Prior Period
- Revenue Growth: Product revenue increased by $76.5 million (55.5%) year-over-year, driven primarily by increased patient enrollment for ARCALYST.
- Profitability: Net income more than doubled to $22.6 million, supported by revenue growth and higher interest income ($3.4 million vs. $2.3 million).
- Expense Increases:
- Collaboration Expenses: Rose to $75.6 million (from $43.8 million) due to the profit-sharing agreement with Regeneron tied to higher ARCALYST sales.
- R&D Expenses: Increased to $27.5 million (from $19.3 million). This was driven by a $11.0 million increase in KPL-387 costs (Phase 2/3 trial enrollment) and a $0.9 million increase in KPL-1161 pre-clinical costs, partially offset by a $4.3 million decrease in abiprubart costs following its discontinuation.
- SG&A Expenses: Increased to $61.2 million (from $43.5 million) due to higher headcount and promotional activities.
- Inventory: Total inventory increased to $78.2 million (from $59.9 million), including $21.1 million in semi-finished goods related to the technology transfer of ARCALYST manufacturing to Samsung Biologics.
Guidance, Outlook, and Risks
- Liquidity: Management expects existing cash, cash equivalents, and short-term investments ($468.1 million) to fund operations for at least the next 12 months.
- Development Milestones:
- KPL-387: Phase 2 data expected in H2 2026; pivotal Phase 3 trial expected to initiate by end of 2026.
- KPL-1161: Phase 1 first-in-human trial expected to initiate by end of 2026.
- ARCALYST: FDA accepted supplemental BLA for technology transfer to Samsung Biologics in April 2026, with a target action date of June 19, 2026.
- Commitments: The company has minimum purchase commitments of $157.3 million under manufacturing and CDMO agreements, with $70.0 million due within one year. Potential contingent payments include up to $570 million from Genentech and $50 million from Huadong.
- Risks: Reliance on ARCALYST for revenue; risks associated with clinical trial outcomes for KPL-387 and KPL-1161; regulatory approval for manufacturing transfer; and competition in the recurrent pericarditis market.
Investor Verification Checklist
- Verify the timeline and regulatory status of the ARCALYST manufacturing technology transfer to Samsung Biologics (target action date June 19, 2026).
- Monitor enrollment rates and data readout timing for the KPL-387 Phase 2/3 trial in recurrent pericarditis.
- Review the sustainability of ARCALYST revenue growth given the profit-sharing arrangement with Regeneron (collaboration expenses rose significantly).
- Assess the impact of the discontinued abiprubart program on future R&D spend allocation.
- Confirm the status of the $20 million milestone payment received from Huadong in Q1 2025 and future royalty expectations.